GlassScriptPhysician profile
Driola Brahaj
NPI 1316151863
$548.33
in general payments reported to CMS, 2019-2025
16 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.73 · 2020: $16.42 · 2021: $17.56 · 2022: $39.32 · 2023: $110 · 2024: $86.02 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.06 |
| Education | $169.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $95.95 | 2025 | |
| Pharmacosmos Therapeutics INC. | $64.02 | 2024 | Monoferric |
| Genentech USA, INC. | $61.83 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $51.20 | 2022-2023 | Empaveli |
| Mirati Therapeutics, INC. | $49.67 | 2023 | Krazati |
| Incyte Corporation | $36.19 | 2023-2025 | Jakafi |
| Celgene Corporation | $28.75 | 2025 | Reblozyl |
| Geron Corporation | $23.87 | 2025 | Rytelo |
| Amag Pharmaceuticals, INC. | $22.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Galvanize Therapeutics, INC | $19.26 | 2025 | Aliya System |
| Janssen Biotech, INC. | $18.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.42 | 2020 | |
| Seagen INC. | $14.30 | 2023 | Adcetris |
| Pfizer INC. | $13.04 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Driola Brahaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.